Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to -$1.4 million.

  • Pulmonx's Change in Receivables fell 49275.77% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 7095.56%. This contributed to the annual value of $1.3 million for FY2024, which is 5786.08% down from last year.
  • Per Pulmonx's latest filing, its Change in Receivables stood at -$1.4 million for Q3 2025, which was down 49275.77% from $1.2 million recorded in Q2 2025.
  • Pulmonx's 5-year Change in Receivables high stood at $1.8 million for Q4 2023, and its period low was -$1.4 million during Q3 2025.
  • For the 5-year period, Pulmonx's Change in Receivables averaged around $503421.1, with its median value being $715000.0 (2023).
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 79341.32% in 2023, then crashed by 49275.77% in 2025.
  • Pulmonx's Change in Receivables (Quarter) stood at -$387000.0 in 2021, then soared by 431.78% to $1.3 million in 2022, then surged by 37.23% to $1.8 million in 2023, then fell by 1.19% to $1.7 million in 2024, then tumbled by 180.99% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, $1.2 million for Q2 2025, and $721000.0 during Q1 2025.